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Summary
Vaccines are considered the bedrock of preventive medicine. However, for 
many pathogens, it has been challenging to develop vaccines that stimulate 
protective, long-lasting immunity. We have developed a novel approach 
using β-1,3-D-glucans (BGs), natural polysaccharides abundantly present 
in fungal cell walls, as a biomaterial platform for vaccine delivery. BGs 
simultaneously provide for receptor-targeted antigen delivery to specialized 
antigen-presenting cells together with adjuvant properties to stimulate 
antigen-specific and trained non-specific immune responses. This review 
focuses on various approaches of using BG particles (GPs) to develop 
bacterial and fungal vaccine candidates. A special case history for the 
development of an effective GP tularaemia vaccine candidate is highlighted.
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Introduction
β-1,3-D-glucans (BG) as a biomaterial for vaccines
BGs are abundant polysaccharides naturally found in fungal, 
bacterial and algae cell walls, without any mammalian coun-
terparts [1]. Structurally, they are composed of linear chains 
of β-1-3 glucopyranosyl residues with periodic β-1,6-linked 
branches. Based on the source, growth and isolation condi-
tions, BGs with varying cell wall constituents (mannose, 
chitin), different branching patterns and sizes can be obtained. 
Each of these biomaterials act as a pathogen-associated 
molecular pattern (PAMP) engaging different receptors of 
antigen-presenting cells (APC), leading to varying immune 
responses [2–4]. Additionally, they are classified as ‘generally 
regarded as safe’ (GRAS) materials and used orally as a 
nutraceutical. Based on their solubility, BGs can be classified 
as soluble glucans or insoluble glucan particles (GPs), each 
of which may act as a biological response modifier (BRM) 
[5]. This review mainly focuses on the use of yeast-derived 
GPs as a vaccine development platform.
Mechanisms of immune modulation by BGs
The power of using BGs for vaccine development lies in 
their ability to stimulate all three arms of immunity: innate, 
trained and adaptive. Like other fungal components, BGs 
act as PAMPs that are recognized by macrophage- or 
dendritic cell (DC)-specific transmembrane pattern 
recognition receptors (PRRs) such as Dectin-1 or 
complement receptor 3 (CR3) [6]. Glucan binding to these 
PRRs leads to a cascade of signalling events resulting in 
phagocytosis of the glucan shell, release of proinflammatory 
cytokines, chemokines, anti-microbial proteins (lysozyme, 
defensins) and enhanced oxidative burst. Formation of 
the Dectin-1-GP phagocytic synapse is crucial for 
phagolysosomal maturation and release of cytokines by 
spleen tyrosine kinase (Syk) [7]-dependent caspase 
recruitment domain family member 9 (CARD9), nuclear 
factor kappa B (NF-κB)-inducing kinase (NIK), nuclear 
factor of activated T cells (NFAT) and independent path-
ways (Raf-1) [7–12]. Dendritic cell (DC) activation via 
glucan stimulation of the dectin-1-Syk-CARD9 pathway 
results in production of proinflammatory cytokines such 
as interleukin (IL)-6, tumour necrosis factor (TNF)-α and 
IL-12p40 in a Toll-like receptor (TLR)-independent manner 
[13]. Such an activation, together with transforming growth 
factor [(TGF)-β, secreted by T regulatory cells], polarizes 
CD4+ T cells towards a T helper type 1 (Th1) and Th17 
fate upon fungal infection in vivo. In human DCs, Th17 
cell expansion is also mediated by glucan stimulation of 
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prostanoid lipid mediator [prostaglandin E2 (PGE2)] 
expression, which in turn results in enhanced IL-23 
production [14]. Dectin-1-Syk activation also triggers light 
chain 3-associated autophagy, which augments epitope 
presentation by recruitment of major histocompatibility 
complex class II (MHC-II) to the phagosomes of APCs 
[15]. BGs also potently activate the alternative pathway 
of complement, resulting in deposition of fragments of 
the third component of complement (C3) on the surface 
of GPs, which are then recognized by complement receptors 
on phagocytes [16]. Additionally, BG-activated leucocytes 
together with anti-tumour antibodies (natural or 
transferred) result in enhanced cytotoxicity against 
C3-opsonized (iC3b) tumour cells, thereby increasing the 
tumoricidal potential of antibodies and targeting tumours 
that are CR3-cytotoxic resistant [17,18].
Apart from Dectin-1- and CR3-mediated signalling, there 
are PAMPs recognized by host TLRs. The immu-
nomodulatory properties of BG differed when co- 
administered with TLR agonists. For example, combining 
lipopolysaccharide (LPS) with GPs magnified the production 
of proinflammatory cytokines such as TNF-α in a myeloid 
differentiation primary response 88 (Myd88)-dependent 
manner [19]. This synergy was unaffected by type-II 
interferon (IFN)-γ priming in murine and human DCs [19].
During the past few years many studies have reported 
that innate immune cells, upon encountering a pathogen 
during infection or vaccination, can be trained to exhibit 
a heightened non-specific but protective immune response 
during reinfection or secondary stimulation by the same 
or a separate pathogen [20,21]. This innate immunological 
memory, often called trained innate immunity (TII), has 
been demonstrated by the protective effects of pretreatment 
of BG prior to pathogen infection. Glucan uptake by 
monocytes and macrophages results in induction of TII 
by stable epigenetic reprogramming that alters the cell’s 
metabolic state [a shift towards glycolysis through the 
protein kinase B/mammalian target of rapamycin/hypoxia-
inducible factor-α (Akt/mTOR/HIFα) pathway] and 
heightened cytokine production [20,22,23]. Unlike TII 
induction by bacillus Calmette–Guérin (BCG) vaccination, 
which lasted up to a year [24], BG priming immune 
responses are short-lived, as they were not observed 20 days 
post-dosing with BG [25].
Glucan particles
GPs are highly purified 3–4  µm hollow porous cell wall 
microspheres composed primarily of BG, typically isolated 
from Saccharomyces cerevisiae, using a series of hot alkaline, 
acid and organic extractions [26]. Owing to their 
immunomodulatory properties, GPs have been explored 
for vaccine delivery and stimulating the immune system. 
There are three general approaches to using GPs in vaccines 
(Fig. 1): (i) as a co-administered adjuvant with antigen(s) 
to enhance T and B cell-mediated immune responses, (ii) 
chemically cross-linked with antigens to provide for both 
antigen delivery and adjuvant functions and (iii) as a 
physical delivery vehicle of antigens trapped inside the 
hollow GP cavity, to provide targeted antigen delivery to 
APCs for tailored T and B cell-mediated immune responses. 
Each of these strategies is further explained in the following 
sections.
Vaccination with GPs and antigens results in enhanced 
antigen-specific CD4+ helper T cells and CD8+ cytotoxic 
T cells (CTL), with a bias towards Th1 (IFN-γ) and Th17 
(IL-17) proinflammatory responses [27]. Apart from these 
responses, GPs also enhance antibody responses after 
vaccination. The immune responses are often long-lasting 
and can persist throughout the lifetime of the vaccinated 
animal. Thus, GP-based vaccines stimulate well-rounded 
immune responses via a combination of their adjuvant 
and antigen delivery properties.
GPs co-administered with vaccines/antigens/
adjuvants
Antigen-specific adaptive immune responses can be 
enhanced by co-administering BG together with antigens 
[28,29]. In this strategy, both innate as well as adaptive 
immune responses are activated to exert protective 
responses against pathogens. Immunizations with a killed 
Trypanosoma cruzi vaccine adjuvanted with GPs resulted 
in 85% survival of mice challenged with T. cruzi [30]. 
In contrast, controls that received dextrose, glucan or 
vaccine alone had 100% mortality [30]. Oral or 
subcutaneous immunizations with zymosan (a crude 
preparation of S. cerevisiae cell walls that contain BG 
and mannans) and dinitrophenyl-keyhole limpet 
haemocyanin in chicks led to induction of protective 
antigen-specific antibodies [31]. GPs enhanced the efficacy 
of a Venezuelan equine encephalitis vaccine more 
effectively than other adjuvants, including Freud’s complete 
adjuvant, highlighting the use of GP as an adjuvant in 
boosting immunity [32]. Synergistic effects of enhanced 
proinflammatory cytokine release and expression of 
co-stimulatory markers were also seen in mice treated 
with zymosan–polyriboinocinic:polyribocytidylic acid 
[poly(I:C)] and inactivated influenza vaccine [33]. Thus, 
GPs not only serve as an adjuvant, but also can enhance 
the activity of other adjuvants.
GPs covalently cross-linked to antigens
The carbohydrate surface of GPs can be covalently 
modified using sodium periodate (NaIO4) oxidation–boro-
hydride reduction, carbodiimide-cross-linking or 1-cyano-
4-dimethylaminopyridinium tetrafluoroborate-mediated 
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conjugation of antigens to the GP shell. GPs cross-linked 
to ovalbumin (OVA) using the carbodiimide method acti-
vated bone marrow-derived DCs to prime OVA-specific 
CD4+ and CD8+ T cells in vitro [34,35]. OVA can be 
cross-linked to periodate-oxidized GPs with 20% coupling 
efficiency (calculated on a weight basis). This is equivalent 
to ~ 5  ×  105 OVA/GP. When mice were subcutaneously 
immunized with GP-OVA and then challenged with OVA-
expressing E.G7 lymphoma cells, significant reductions in 
tumour size were observed compared to groups receiving 
OVA or GP alone [34]. GP-OVA were found in the DCs 
(CD11c+MHC-II+) in lymph nodes 12 and 36  h post-
subcutaneous injection [34]. The tumour protective effects 
were associated with an increase in total immunoglobulin 
(Ig)G titre, enhanced MHC-II and co-stimulatory molecule 
(CD80, CD86) expression and heightened CTL responses 
[34,35]. In infection models, administration of GPs con-
jugated to bovine serum albumin (BSA) at a lower dose 
(0·6 mg) protected mice challenged with the fungal patho-
gens Aspergillus fumigatus and Coccidioides posadasii mar-
ginally more effectively than GP-alone immunization 
[36,37]. The exact reason for a slightly better protective 
response is unclear, although few of the colony-stimulating 
factors, cytokines and chemokines were marginally 
enhanced in the whole glucan particles (WGP)-BSA vac-
cinated mice, suggesting that the protective effects were 
governed by activation of both innate and adaptive immu-
nity. Interestingly, there were no substantial changes in 
the anti-β-glucan antibodies in these vaccinated mice, 
implying that antibodies against glucans do not contribute 
significantly to the protective immune response. Soluble 
glucan (laminarin) conjugated to a detoxified mutant 
diphtheria toxin (CRM197) has been tested as a pan 
fungal vaccine [38] for generation of efficient anti-glucan 
antibodies. One of the major limitations of surface con-
jugation methods is the low coupling efficiency (20%) 
compared to antigen encapsulation in GPs, limiting the 
number of vaccine candidates utilizing this strategy. 
Additionally, immune response to surface- versus core-
loaded antigens may differ significantly, as exemplified in 
the case of Francisella tularensis vaccine explained later 
in this review.
Fig. 1. Diagram showing different methods of vaccinations using β-1,3-D-glucans (BG) particles (GPs). Purified GPs can be employed as a vaccination 
platform by co-administration, cross-linking and encapsulation of antigens.
A. Abraham et al.
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GPs with non-covalently encapsulated antigens for 
vaccine delivery
The elegance of using GPs as a vaccine delivery platform 
is that it can serve as both a carrier of antigens in its 
hollow core, target antigens to APCs via receptor-mediated 
phagocytosis and concurrently acts as an adjuvant, thereby 
reducing the antigen dosage by ~ 100-fold [27,39]. Moreover, 
it can encapsulate one or more antigens/DNA/RNA/
adjuvants/drugs/combinations with greater than 90% 
loading efficiency. The strategy of encapsulation is dictated 
by the type of payload and the mode of delivery. Antigens 
can be encapsulated in the hollow cavity of the GPs using 
polymer nano-complexation methods [26]. Using this 
strategy, Huang et al reported that mice vaccinated with 
GP–OVA showed strong CD4+ T cell lymphoproliferation, 
a Th1 and Th17 skewed T cell-mediated immune response 
together with high IgG1- and IgG2c-specific antibody 
responses [39]. The non-covalent encapsulation strategy 
elicited stronger immune responses compared to GPs 
co-administered with antigen. Moreover, antigen-specific 
T cell and antibody responses remained robust 20 months 
following the last immunization [39].
Subunit vaccines with GPs encasing soluble alkaline 
extracts of Cryptococcus neoformans acapsular strain 
(cap59) protected mice challenged with lethal doses of 
highly virulent C. neoformans (60% survival) by inducing 
an antigen-specific CD4+ T cell response (positive for 
IFN-γ, IL-17a) that reduced the fungal colony-forming 
units (CFU) more than 100-fold from the initial challenge 
dose [40,41]. A similar strategy of vaccinating mice with 
GP encapsulating antigens proved efficacious against 
Histoplasma capsulatum [42], F. tularensis [43], Blastomyces 
dermatitidis [44] and C. posadasii [45]. The versatility of 
using GPs vaccines against microbial pathogens is 
summarized in Table 1.
Identification of immunologically relevant epitopes aids 
the development of recombinant peptides/polypeptides that 
can be encapsulated within GPs for generating antigen-
specific protective immunity. For example, recombinant 
chimeric poly-epitope antigen (rCpa1), consisting of a 
combination of three different antigens and five MHC-II 
binding pathogen-derived peptides, was designed for a C. 
posadasii vaccine [46]. When administered together with 
a TLR-9 agonist [DNA containing unmethylated cytosine–
phosphate–guanine oligonucleotides (CpG-ODN)], a non-
protective immune response was induced in a humanized 
human leucocyte antigen (HLA)-DR4 transgenic mouse 
model. However, immunization with a GP-rCpa1 formula-
tion resulted in an enhanced Th1- and Th17-based pro-
tective immune response. Upon further optimization, yeast 
particles containing different cell wall constituents were 
used to synthesize similar encapsulated rCpa1 vaccines. 
Vaccines prepared with glucan chitin particles (GCPs) 
showed enhanced protection compared to GP or GP 
mannoprotein-based vaccines, suggesting that additional 
PAMPs in these more complex particles enhanced protective 
immune responses [46]. A single conserved antigen can 
also confer cross-protection to different fungal pathogens, 
as demonstrated by protective responses of calnexin 
encapsulated in GP vaccine against B. dermatitidis and 
C. posadasii [44].
In summary, GP-encapsulated antigen vaccines provide 
stronger immune responses than co-administered GP or 
GP-cross-linked antigen vaccination strategies. Importantly, 
GP vaccines stimulate Th1/Th17-biased immune responses, 
which are being recognized as necessary for protection 
against a growing number of pathogens. The adjuvanticity 
of glucans can sometimes be enhanced by loading GPs 
with other adjuvants such as alum and TLR agonists, etc. 
[47]. These attributes demonstrate the potential of the 
GP encapsulation technology for antigen discovery and 
vaccine development. As an example, our work on the 
development a GP-based vaccine against tularaemia is 
discussed below.
Tularaemia: a challenge for vaccinology
F. tularensis is an intracellular pathogen and the causative 
agent of the disease tularaemia. Capable of infecting a 
wide range of hosts, its normal zoonotic hosts are rodents 
and lagomorphs, but humans can be accidental hosts. The 
most common form of human tularaemia is ulceroglandular 
tularaemia, which arises following the bite of an infected 
insect or arthropod vector. However, it was reported recently 
that almost half the isolates studied from human cases 
in Nebraska were cat-associated, with transmission by bites 
and scratches [48]. In humans, the most acute presentation 
is respiratory or pneumonic tularaemia, following inhalation 
of infectious aerosols. The organism has a very low aerosol 
infectious dose for humans, requiring fewer than 50 CFU 
to establish respiratory infection [49]. Following inhalation, 
the most highly virulent strains can have a case fatality 
rate of up to 30% if untreated, but appropriate antibiotic 
therapy reduces this to approximately 2% [50]. Diagnosis 
based on symptoms is difficult, as the presentation can 
range from mild pneumonia to an acute infection with 
high fever, malaise, chills, cough, delirium and pulse–
temperature dissociation, all of which are extremely non-
specific. The high aerosol infectivity, morbidity and 
mortality led to the organism being developed as a biological 
weapon by various nations, including the reported 
production of antibiotic-resistant strains [50,51]. 
Tularaemia responds well to timely antibiotic therapy. 
Aminoglycosides, particularly streptomycin, have been used 
extensively for the treatment of tularaemia, but streptomycin 
is rarely used now due to adverse side effects, and gentamicin 
is a suitable alternative which has been used to treat cases 
Francisella tularensis and other pathogens
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Table 1. β-1,3-D-glucan particles (GP) encapsulated vaccines against microbial pathogens. Different types of GPs can be formulated with a variety of 
antigens to stimulate antibody, T helper type 1 (Th1)- and Th17-biased immune responses that protect against numerous microbial pathogens in 
separate animal models
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of pneumonic tularaemia on Martha’s Vineyard [52]. 
However, aminoglycosides are reserved for the most serious 
cases due to the requirement for parenteral dosing and 
monitoring of serum levels. Ciprofloxacin is currently the 
preferred choice of drug for the oral treatment of 
uncomplicated tularaemia [50]. Relapse is common 
following short courses and some patients may require 
respiratory support and intensive care should sepsis develop. 
Suppurating nodes are a common cause of treatment 
failure, and these may require draining [53]. Failure can 
also arise as a result of delayed initiation of antibiotics 
or if therapy is withdrawn prematurely (reviewed by Caspar 
et al. [54]) As such, there is strong interest in developing 
effective medical countermeasures to prevent and treat 
tularaemia, particularly vaccines.
Many different approaches have been explored in the 
quest for a safe effective vaccine to protect against 
tularaemia. Crude culture extracts [55–58], subunit vaccines 
and attenuated strains have all been evaluated, but none 
meet the criteria of efficacy and safety required for a 
modern vaccine. The most promising candidates were 
purified LPS and the ‘Live Vaccine Strain’ (LVS). Purified 
Francisella LPS induced a humoral response that was able 
to protect mice against low virulence strains of F. tularensis 
[59,60], but only extended the time to death following 
challenge with more virulent strains. Despite extensive 
screening, no protein antigens were identified to supplement 
the protection induced by LPS. In contrast, LVS, having 
been used in many thousands of humans under 
Investigational New Drug status, seems to be effective for 
the prevention of respiratory tularaemia in humans [61], 
but has safety concerns associated with its use, and thus 
the LVS strain has yet to be approved by regulatory bodies. 
We hypothesized that subunit vaccines are most attractive 
due to their defined nature and thus good safety profiles, 
but that we needed to deliver promising candidate antigens 
in a manner that induced both humoral and cellular 
immune responses to achieve protection, as only a balanced 
humoral and cellular immune memory response, supported 
by innate immune mechanisms, protects against tularaemia 
(reviewed by Roberts et al. [62] and Krokova et al. [63]). 
We therefore decided to employ the GP vaccine delivery 
platform described above to address this challenge [43]. 
This work is summarized below.
A panel of 28 Francisella proteins was selected for 
evaluation in the GP platform, the majority of which had 
been identified by the approach described in [64]. Many 
of these had been evaluated previously as potential vaccine 
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GCP  =  GP containing chitin, GMP  =  GP containing mannose; Cda2  =  chitin deacetylase 2; CpG-ODN  =  ssDNA with unmethylated cytosine–
phosphate–guanine (CpG) oligonucleotides; HLA-DR4: transgenic mice containing a hybrid major histocompatibility complex class II (MHC-II) with 
human leucocyte antigen peptide binding domains; rCpa1: recombinant chimeric polypeptide antigen; Th = T helper; CFU = colony-forming units; 
IFN = interferon; Ig = immunoglobulin; NOD = nucleotide oligomerization domain.
Table 1. Continued
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antigens using other adjuvants without success. These 
proteins were expressed recombinantly in Escherichia coli 
and purified. Initial expression analysis showed some of 
the proteins to be relatively insoluble, and thus our standard 
GP loading conditions were modified to include 6 M urea, 
which was subsequently removed by washing [65]. In 
addition, LPS was loaded either onto the surface of the 
GPs or into the core. However, the GP core-loaded F. 
tularensis LPS formulations were more immunostimulatory 
than surface-linked F. tularensis LPS GP formulations or 
free biotinylated F. tularensis LPS. Therefore, core-loaded 
Francisella LPS was selected for further evaluation as a 
component of the GP-delivered vaccine.
The mouse is a good model for immunological analysis 
of tularaemia vaccines, but its acute susceptibility means 
that it is difficult to induce protection. The LVS strain 
can induce protection in mice, and correlates of protection 
are being determined [66,67]. However, no correlates in 
mice have been identified for subunit vaccines, other than 
the need for antibody titres against LPS [59,60], which 
are not sufficient on their own to protect against infection 
with fully virulent strains of F. tularensis [59]. The selection 
of promising candidates to progress to the next round of 
screening was primarily influenced by a combination of 
the development of antigen-specific IFN-γ enzyme-linked 
immunospot (ELISPOT) responses and/or the detection 
of an antibody response, particularly where an IgG2a bias 
was observed. As there are currently no robust correlates 
of protection known for tularaemia vaccines, we were 
interested in selecting candidates that represented a variety 
of immune response profiles, albeit with a bias towards 
cell-mediated immunity. This allowed us to identify seven 
proteins of interest: IgIC, FTT0071, FTT0289, FTT0438, 
FTT0814, FTT0890 and FTT1043. As IglC has been 
previously reported to induce partial protection in animals 
(reviewed by Roberts et al. [62] and Krokova et al. [63]) 
this was also included, even though the IglC GP vaccine 
induced poor immune responses. However, consistent with 
our selection rationale, it did not perform well later, and 
was subsequently dropped. T cell memory recall responses 
induced in splenocyte cultures from immunized C57Bl/6 
mice showed that FTT0071, FTT0814 and FTT0890 were 
the most potent inducers of IFN-γ responses. FTT0814 
stimulated the strongest and most consistent IL-10 response. 
However, there was no protection induced in immunized 
mice against challenge with a similar dose of F. tularensis.
The Fischer 344 rat has been proposed as a more 
appropriate model for F. tularensis vaccine efficacy testing, 
as it is more resistant to tularaemia than the highly 
susceptible mouse model, and overall the pathogenesis of 
respiratory tularaemia in the rat model appears to replicate 
tularaemia in humans [68]. Strain SchuS4 is a highly 
virulent strain, and injection of mice with a dose of 1 CFU 
results in 100% mortality. As rats are more resistant, a 
higher bacterial dose of 1·6  ×  103 CFU of F. tularensis 
SchuS4 delivered via the respiratory route was determined 
to achieve 100% lethality in PBS-treated controls. An 
immunological bridging study was first undertaken to 
determine the hierarchy of immunological responsiveness 
of the seven down-selected F. tularensis antigens in rats. 
Responses to the carrier protein, OVA, included in each 
vaccine were lower than seen in the mouse, but it has 
previously been reported that Fischer rats are ‘low 
immunological responders’ to OVA even when compared 
with other rat strains, such as Wistar and Sprague–Dawley 
rats [69]. While the hierarchy of immune responsiveness 
in mouse and rat models was largely overlapping, FTT0071 
was a notable exception, and while this antigen was 
immunodominant with regard to IgG and IFN-γ responses 
in mice, it induced poor responses in rats. Further evaluation 
of responses in rats showed that immunization with the 
FTT0814-based GP vaccine induced the strongest and 
most consistent antigen-specific IgG response and the 
strongest T cell-mediated IFN-γ responses. In challenge 
studies, all GP-encapsulated F. tularensis antigen 
combinations containing LPS were able to protect rats 
against an otherwise lethal aerosol challenge of F. tularensis 
SchuS4. Only the GP-FTT0814-LPS vaccine was able to 
prevent the development of any clinical scores in rats to 
the same extent as LVS (Fig. 2). This is suggestive that 
FTT0814 may supplement the protection induced by LPS 
when delivered by GPs. This is an impressive step forward 
towards developing a subunit vaccine to prevent tularaemia 
and demonstrates the broad immunological responses that 
can be induced by GP technology. It also highlights the 
importance of using an appropriate animal model for 
efficacy studies versus immunogenicity screens.
Future of GP vaccines
Heat-killed yeast expressing antigens (intracellularly or surface 
displayed) have been used as a vaccine vector to generate 
antigen-specific adaptive immune responses [70]. Clinical 
trials confirm that these vaccinations result in minimal 
toxicity to humans [71]. However, such a mode of vaccination 
can result in delivery of yeast-derived peptides into the 
host cell and the presence of other components (such as 
mannans, chitins) might have additional role in immune 
responses. As glucans are the major immunomodulatory 
component of the yeast cell walls, the use of purified GPs 
as a vaccine vector have been investigated. A stepwise process 
for development of GP-based vaccine is depicted in Fig. 3. 
Briefly, the first step involves discovery of protective antigens 
and in-vivo testing of recombinantly expressed antigens that 
are encapsulated within GPs. After identification of lead 
antigens, the GP-based formulations will be further optimized 
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with respect to type of GP, antigen(s)/adjuvant(s) and mode 
of vaccination. The lead vaccine candidate/candidates will 
be manufactured under cGMP. An Investigational New Drug 
(IND) application will be submitted to the Food and Drug 
Administration (FDA), upon approval of which the vaccines 
can be tested in humans. Following successful clinical trials, 
a Biological License Application (BLA) will be submitted 
that enables commercialization of the vaccine.
GPs offer significant advantages over other adjuvants 
and vaccine delivery systems. GP vaccines have been 
shown to be protective against bacterial, fungal and viral 
infections, as well as in animal models of cancer. Immune 
responses to GP vaccines have been elicited following 
multiple routes of delivery, including subcutaneous, 
intramuscular, pulmonary and oral [72]. While most 
studies have been preclinical, there have been promising 
Phase I/II clinical trials demonstrating that BGs [73] and 
GPs [74] are well tolerated in humans. Understanding 
the basis of protective host immunity for specific 
infections, and how BGs interact with immune cells to 
enhance immunity, will hopefully pave the way for 
development of optimal BG-based vaccines.
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